Profiles

Keywords
Last Name
Institution

John Somberg

Concepts (591)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Anti-Arrhythmia Agents
56
2019
90
8.650
Why?
Drug Approval
19
2013
34
6.390
Why?
United States Food and Drug Administration
36
2014
73
6.270
Why?
Drug Industry
21
2013
28
4.870
Why?
Electrocardiography
49
2015
197
4.490
Why?
Clinical Trials as Topic
26
2014
369
4.380
Why?
United States
72
2014
2119
4.150
Why?
Arrhythmias, Cardiac
37
2019
134
4.140
Why?
Amiodarone
18
2016
28
4.050
Why?
Pharmaceutical Preparations
10
2012
18
3.990
Why?
Device Approval
8
2014
17
3.710
Why?
Humans
214
2019
26828
3.690
Why?
Drug-Related Side Effects and Adverse Reactions
12
2018
32
3.450
Why?
Heart Failure
14
2015
184
3.000
Why?
Drug Design
6
2014
37
2.910
Why?
Tachycardia
33
2013
43
2.790
Why?
Equipment Design
8
2014
181
2.650
Why?
Research
12
2014
58
2.630
Why?
Equipment and Supplies
5
2011
14
2.530
Why?
Diuretics
6
2009
13
2.480
Why?
Drug Prescriptions
8
2008
28
2.420
Why?
Hypertension
8
2015
218
2.370
Why?
Sotalol
8
2019
8
2.140
Why?
Long QT Syndrome
7
2011
13
2.130
Why?
Atrial Fibrillation
9
2016
134
2.130
Why?
Ether-A-Go-Go Potassium Channels
5
2008
8
2.000
Why?
Caffeine
3
2015
60
2.000
Why?
Cardiovascular Agents
6
2015
29
1.970
Why?
Periodicals as Topic
5
2015
34
1.930
Why?
Endpoint Determination
4
2014
29
1.780
Why?
Patents as Topic
4
2014
5
1.720
Why?
Blood Pressure
18
2015
210
1.690
Why?
Cardiovascular Diseases
7
2014
316
1.630
Why?
Publishing
4
2015
34
1.570
Why?
Politics
5
2010
17
1.500
Why?
Drug Labeling
4
2010
6
1.500
Why?
Research Support as Topic
5
2013
20
1.490
Why?
Legislation, Drug
5
2008
5
1.470
Why?
Myocardial Infarction
10
2009
175
1.410
Why?
Drug Costs
5
2015
16
1.400
Why?
Biomedical Research
4
2013
80
1.370
Why?
Delivery of Health Care
3
2015
77
1.340
Why?
Central Nervous System Stimulants
2
2015
54
1.320
Why?
Advisory Committees
3
2013
39
1.310
Why?
Analgesics
2
2015
95
1.270
Why?
Product Surveillance, Postmarketing
7
2010
17
1.260
Why?
Chronic Pain
2
2015
82
1.260
Why?
Drug Therapy
5
2012
15
1.210
Why?
Piperidines
17
1987
34
1.190
Why?
Financing, Government
4
2013
14
1.180
Why?
Heart Rate
17
2015
146
1.180
Why?
Disease Outbreaks
3
2014
83
1.150
Why?
Risk Assessment
6
2014
723
1.110
Why?
Conflict of Interest
3
2013
18
1.090
Why?
Vasodilator Agents
5
2009
28
1.090
Why?
Infusions, Intravenous
10
2011
98
1.040
Why?
Female
69
2015
16022
1.010
Why?
Male
74
2019
15627
1.010
Why?
Angiotensin-Converting Enzyme Inhibitors
5
2002
28
0.980
Why?
Hypotension
4
2005
28
0.980
Why?
Health Care Reform
2
2011
17
0.950
Why?
Health Policy
3
2014
42
0.930
Why?
Benzeneacetamides
11
1986
12
0.920
Why?
Quinidine
12
2007
14
0.910
Why?
Genetic Testing
3
2012
71
0.910
Why?
Evidence-Based Medicine
4
2009
215
0.910
Why?
Animals
27
2009
4877
0.900
Why?
Ethacrynic Acid
2
2009
3
0.890
Why?
Randomized Controlled Trials as Topic
3
2014
314
0.890
Why?
Lidocaine
12
2004
42
0.860
Why?
Oocytes
6
2008
14
0.860
Why?
Edema
2
2009
40
0.850
Why?
Internet
2
2015
84
0.830
Why?
Electrophysiology
18
2007
141
0.820
Why?
Sex Characteristics
3
2015
94
0.800
Why?
Drug Combinations
2
2015
84
0.790
Why?
Stroke
2
2011
316
0.780
Why?
Dose-Response Relationship, Drug
14
2010
511
0.770
Why?
Potassium Channels, Voltage-Gated
3
2006
13
0.760
Why?
Time Factors
19
2012
1741
0.760
Why?
Procainamide
19
1987
20
0.760
Why?
Education, Medical, Continuing
2
2008
46
0.750
Why?
Drug Interactions
6
2010
69
0.750
Why?
Digoxin
3
2014
6
0.740
Why?
Platelet Aggregation Inhibitors
4
2010
63
0.730
Why?
Hypoglycemic Agents
2
2010
72
0.720
Why?
Hemodynamics
11
2004
100
0.710
Why?
Diffusion of Innovation
2
2008
37
0.710
Why?
Aminobutyrates
1
2015
1
0.710
Why?
Tetrazoles
1
2015
6
0.700
Why?
Energy Drinks
1
2015
1
0.700
Why?
Syncope, Vasovagal
2
2009
2
0.700
Why?
Coffee
1
2015
4
0.700
Why?
Drug Utilization
3
2006
21
0.700
Why?
Manometry
1
2015
27
0.700
Why?
Thyroid Gland
1
2016
55
0.700
Why?
Nicotine
1
2015
8
0.700
Why?
Global Health
2
2014
53
0.690
Why?
Research Design
3
2007
189
0.690
Why?
Diabetic Neuropathies
1
2015
14
0.680
Why?
Myocardial Ischemia
3
2009
52
0.680
Why?
Kidney
2
2015
189
0.680
Why?
Flecainide
9
2008
12
0.680
Why?
Denervation
1
2015
20
0.670
Why?
Computers
1
2015
19
0.670
Why?
Endothelium, Vascular
1
2015
70
0.670
Why?
Death, Sudden, Cardiac
3
2000
23
0.670
Why?
Hemorrhagic Fever, Ebola
1
2014
7
0.660
Why?
Sports
2
2008
23
0.650
Why?
Biological Products
2
2007
28
0.650
Why?
Middle Aged
52
2010
10136
0.650
Why?
Defibrillators, Implantable
2
2013
21
0.640
Why?
Public Health
1
2014
48
0.640
Why?
Medical Device Recalls
1
2014
3
0.630
Why?
Adult
29
2015
8795
0.630
Why?
Angioplasty, Balloon, Coronary
2
2009
54
0.630
Why?
Practice Guidelines as Topic
2
2012
349
0.630
Why?
Antibodies, Monoclonal
2
2007
305
0.620
Why?
Heart Valve Prosthesis
1
2014
35
0.620
Why?
Patient Care
1
2014
32
0.620
Why?
Communication
1
2015
99
0.610
Why?
Sulfonamides
4
2016
57
0.610
Why?
Pain Management
1
2015
117
0.610
Why?
Supreme Court Decisions
1
2013
1
0.610
Why?
Equipment Safety
2
2010
13
0.610
Why?
Quality Assurance, Health Care
1
2014
53
0.600
Why?
Federal Government
1
2013
4
0.600
Why?
Patient Protection and Affordable Care Act
1
2013
18
0.600
Why?
Genes, BRCA1
1
2013
12
0.600
Why?
Genes, BRCA2
1
2013
12
0.600
Why?
Electrocardiography, Ambulatory
3
2015
19
0.590
Why?
Guidelines as Topic
1
2014
76
0.590
Why?
Torsades de Pointes
3
2011
11
0.590
Why?
Comparative Effectiveness Research
1
2013
7
0.590
Why?
Tachycardia, Ventricular
2
2004
25
0.580
Why?
Piperazines
3
2009
93
0.580
Why?
Cardiac Pacing, Artificial
16
1987
48
0.580
Why?
Xenopus laevis
6
2008
9
0.580
Why?
Registries
2
2004
165
0.570
Why?
Metagenome
1
2012
16
0.560
Why?
Diabetes Mellitus
2
2011
104
0.560
Why?
Action Potentials
4
2006
123
0.560
Why?
Drug and Narcotic Control
2
2010
8
0.560
Why?
Bioterrorism
2
2002
6
0.540
Why?
Antithrombins
1
2011
6
0.540
Why?
Drugs, Generic
2
2002
4
0.530
Why?
Drug Delivery Systems
2
2015
39
0.530
Why?
Therapies, Investigational
1
2011
4
0.530
Why?
Pediatrics
2
2003
44
0.520
Why?
Hypotension, Orthostatic
2
2010
16
0.520
Why?
Risk Factors
9
2016
2316
0.510
Why?
Drug Discovery
1
2011
25
0.510
Why?
Anticholesteremic Agents
2
2008
25
0.510
Why?
Heart Conduction System
7
2002
26
0.510
Why?
Cross Infection
1
2014
274
0.510
Why?
Cyclooxygenase Inhibitors
3
2006
39
0.500
Why?
Product Recalls and Withdrawals
1
2010
1
0.500
Why?
Sympathomimetics
1
2010
5
0.500
Why?
Midodrine
1
2010
2
0.500
Why?
Fibrinolytic Agents
1
2011
88
0.500
Why?
Administration, Oral
12
2016
153
0.500
Why?
Adrenergic beta-Antagonists
7
2016
42
0.490
Why?
Drug Evaluation
10
2002
57
0.490
Why?
Antihypertensive Agents
3
2014
65
0.490
Why?
Angina Pectoris
2
2004
18
0.490
Why?
Potassium
2
2007
65
0.490
Why?
Chemistry, Pharmaceutical
4
2005
14
0.480
Why?
Cytochrome P-450 Enzyme System
1
2010
10
0.480
Why?
Global Warming
1
2010
1
0.480
Why?
Aged
39
2010
8962
0.480
Why?
Hospitalization
2
2014
286
0.480
Why?
Decision Making
1
2012
183
0.470
Why?
Therapeutic Equivalency
5
2016
8
0.470
Why?
Dementia, Vascular
1
2010
40
0.470
Why?
Technetium
1
2009
6
0.460
Why?
Muscle Contraction
2
2007
85
0.460
Why?
Anticoagulants
1
2011
136
0.460
Why?
Cost Control
1
2009
11
0.460
Why?
Thiophenes
1
2009
14
0.460
Why?
Heart Ventricles
18
2008
194
0.460
Why?
Technology, Pharmaceutical
1
2009
2
0.460
Why?
Ventricular Function
2
2008
14
0.460
Why?
Radiopharmaceuticals
1
2009
58
0.450
Why?
Neurology
1
2011
99
0.450
Why?
Ascites
1
2009
5
0.440
Why?
Insulin
1
2010
95
0.440
Why?
Genetics
2
2006
2
0.440
Why?
Natriuretic Peptide, Brain
2
2006
10
0.440
Why?
Medication Errors
2
2000
20
0.440
Why?
Methadone
1
2008
7
0.440
Why?
Patient Selection
2
2007
235
0.440
Why?
Licensure, Medical
1
2008
2
0.440
Why?
Catheter Ablation
1
2009
44
0.430
Why?
Catheterization
1
2009
61
0.430
Why?
Rats
7
2007
918
0.430
Why?
Drug-Eluting Stents
1
2008
13
0.430
Why?
Acidosis
2
2005
5
0.430
Why?
Authorship
1
2008
16
0.430
Why?
Clinical Trials, Phase I as Topic
1
2008
9
0.420
Why?
Substance Abuse Detection
1
2008
5
0.420
Why?
Self Disclosure
1
2008
12
0.420
Why?
Fees and Charges
1
2008
8
0.420
Why?
Signal Processing, Computer-Assisted
1
2008
43
0.420
Why?
Doping in Sports
1
2008
2
0.420
Why?
Enzyme Inhibitors
1
2009
157
0.410
Why?
Food-Drug Interactions
1
2007
1
0.410
Why?
Flavanones
1
2007
3
0.410
Why?
Hypercholesterolemia
1
2008
34
0.410
Why?
Hypolipidemic Agents
2
2014
28
0.410
Why?
Beverages
1
2007
13
0.410
Why?
Heart Diseases
2
2008
91
0.400
Why?
Government Regulation
3
2015
7
0.400
Why?
Ethics Consultation
1
2007
1
0.400
Why?
Heart Septal Defects, Atrial
1
2007
20
0.390
Why?
Metolazone
1
2007
1
0.390
Why?
Diuresis
1
2007
2
0.390
Why?
Furosemide
1
2007
2
0.390
Why?
Physician's Role
1
2007
22
0.390
Why?
Analgesics, Opioid
1
2008
127
0.390
Why?
Graft Occlusion, Vascular
1
2007
21
0.390
Why?
Myocardial Contraction
5
2005
78
0.380
Why?
Databases as Topic
1
2006
20
0.380
Why?
Social Control, Formal
3
2001
4
0.380
Why?
Patch-Clamp Techniques
4
2007
121
0.380
Why?
Gastrointestinal Tract
1
2007
49
0.370
Why?
Pharmacology, Clinical
2
2004
3
0.370
Why?
Electrodes
1
2006
16
0.370
Why?
Information Dissemination
2
2004
19
0.370
Why?
Retrospective Studies
6
2015
2805
0.370
Why?
In Vitro Techniques
4
2007
244
0.360
Why?
Electric Stimulation
12
2004
86
0.360
Why?
Security Measures
2
2003
4
0.360
Why?
Erythromycin
1
2006
11
0.360
Why?
Verapamil
7
2009
34
0.360
Why?
Natriuretic Agents
1
2005
1
0.350
Why?
Hypnotics and Sedatives
1
2006
23
0.350
Why?
Hyperkalemia
2
2006
5
0.350
Why?
Drug Administration Schedule
7
2019
256
0.350
Why?
Pyridines
1
2006
45
0.350
Why?
Administration, Topical
2
2015
23
0.350
Why?
Water
2
2003
36
0.350
Why?
Hypokalemia
2
2005
7
0.340
Why?
Healthy Volunteers
2
2015
39
0.340
Why?
Prostheses and Implants
1
2007
161
0.340
Why?
Magnesium Sulfate
1
2005
9
0.340
Why?
Human Experimentation
2
2002
2
0.340
Why?
Stents
1
2007
146
0.340
Why?
Coronary Disease
4
1998
97
0.330
Why?
Antineoplastic Agents
2
2009
304
0.330
Why?
Young Adult
4
2015
1961
0.330
Why?
Ethics, Medical
2
2001
18
0.320
Why?
Rats, Sprague-Dawley
4
2007
468
0.320
Why?
Anti-Obesity Agents
1
2004
6
0.320
Why?
Liability, Legal
3
2012
6
0.320
Why?
Nonprescription Drugs
1
2004
2
0.320
Why?
Heart Arrest
4
1997
48
0.310
Why?
Prescription Fees
1
2003
1
0.310
Why?
Stereoisomerism
4
2008
22
0.310
Why?
Imidazoles
6
1987
69
0.310
Why?
Sensitivity and Specificity
4
2008
583
0.310
Why?
Publication Bias
1
2003
8
0.300
Why?
Adverse Drug Reaction Reporting Systems
2
2000
7
0.300
Why?
Communicable Diseases, Emerging
1
2003
2
0.300
Why?
Severe Acute Respiratory Syndrome
1
2003
5
0.300
Why?
Teaching
1
2004
62
0.300
Why?
Electric Countershock
5
2013
20
0.300
Why?
Clinical Protocols
2
2003
62
0.300
Why?
Blood Pressure Monitoring, Ambulatory
1
2003
4
0.290
Why?
Glyburide
1
2002
1
0.290
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2004
66
0.290
Why?
Drug Therapy, Combination
4
2009
252
0.280
Why?
Clinical Competence
1
2005
246
0.280
Why?
Metformin
1
2002
21
0.280
Why?
Polymorphism, Genetic
2
2002
89
0.280
Why?
Anti-Bacterial Agents
2
2006
378
0.280
Why?
Facility Regulation and Control
1
2002
2
0.280
Why?
1-Octanol
1
2002
1
0.270
Why?
Solvents
1
2002
6
0.270
Why?
Heart Valve Diseases
1
2002
20
0.270
Why?
Public Health Administration
1
2001
9
0.270
Why?
Disaster Planning
1
2001
8
0.270
Why?
Magnesium Compounds
1
2001
2
0.270
Why?
Emergency Medical Services
1
2001
37
0.260
Why?
Accreditation
1
2001
14
0.260
Why?
Calcium Metabolism Disorders
1
2001
1
0.260
Why?
Orphan Drug Production
1
2001
3
0.260
Why?
Ventricular Dysfunction
1
2001
3
0.260
Why?
Stem Cells
1
2001
49
0.260
Why?
Addison Disease
1
2000
1
0.250
Why?
Government Programs
1
2000
2
0.250
Why?
Obesity
1
2004
287
0.240
Why?
Cross-Over Studies
2
2010
69
0.240
Why?
Genetic Markers
3
2012
49
0.240
Why?
Information Services
1
1999
5
0.230
Why?
Science
1
1999
6
0.230
Why?
Half-Life
4
2009
16
0.230
Why?
Diabetes Mellitus, Type 2
1
2002
197
0.230
Why?
Potassium Channels
3
2006
43
0.230
Why?
Pharmacokinetics
2
2002
6
0.220
Why?
Circadian Rhythm
2
2006
260
0.220
Why?
Cardiac Surgical Procedures
1
2019
81
0.220
Why?
Biological Availability
3
2009
24
0.210
Why?
Dogs
5
2004
277
0.210
Why?
Drug Hypersensitivity
1
1998
18
0.210
Why?
Delayed Rectifier Potassium Channels
2
2007
4
0.210
Why?
Area Under Curve
2
2010
72
0.210
Why?
Alprostadil
1
1997
11
0.210
Why?
Peripheral Vascular Diseases
1
1997
11
0.200
Why?
Arterial Occlusive Diseases
1
1997
18
0.200
Why?
Death, Sudden
4
2004
15
0.200
Why?
Aged, 80 and over
6
2004
4580
0.200
Why?
Heart
5
1992
99
0.190
Why?
Hypertrophy, Left Ventricular
1
1997
28
0.190
Why?
Nitroglycerin
2
1995
4
0.190
Why?
Risk
4
2011
205
0.190
Why?
Universities
2
2010
22
0.190
Why?
Hydrogen-Ion Concentration
2
2007
166
0.180
Why?
Controlled Clinical Trials as Topic
2
2008
6
0.180
Why?
Hydantoins
2
2006
2
0.180
Why?
Imidazolidines
2
2006
2
0.180
Why?
Phenethylamines
2
2006
5
0.180
Why?
Biotechnology
1
2015
3
0.180
Why?
Hypercalcemia
3
2001
8
0.180
Why?
Injections, Intravenous
7
2016
60
0.180
Why?
Adolescent
2
2015
2381
0.180
Why?
Reproducibility of Results
3
2006
778
0.180
Why?
Diclofenac
1
2015
4
0.180
Why?
Treatment Outcome
4
2008
3376
0.180
Why?
Membrane Potentials
2
2007
201
0.180
Why?
Stimulation, Chemical
1
2015
13
0.170
Why?
Ointments
1
2015
3
0.170
Why?
Myocardium
4
2008
175
0.170
Why?
Hypothyroidism
1
2016
68
0.170
Why?
Africa South of the Sahara
1
2014
1
0.170
Why?
Anilides
4
1987
9
0.170
Why?
Journalism, Medical
2
2008
5
0.170
Why?
Antibodies, Monoclonal, Humanized
2
2007
118
0.170
Why?
Ventricular Fibrillation
5
2006
24
0.160
Why?
Sex Factors
2
2008
478
0.160
Why?
Breast Neoplasms
2
2013
405
0.160
Why?
Europe
2
2005
74
0.160
Why?
Phenothiazines
4
1987
4
0.160
Why?
Early Termination of Clinical Trials
1
2014
2
0.160
Why?
Referral and Consultation
1
2015
86
0.160
Why?
Structure-Activity Relationship
2
2005
53
0.160
Why?
Safety
1
2014
55
0.160
Why?
Lobbying
1
2013
1
0.160
Why?
Health Insurance Exchanges
1
2013
1
0.150
Why?
Ouabain
4
1983
6
0.150
Why?
Electricity
1
2013
9
0.150
Why?
Organizational Innovation
2
2003
19
0.150
Why?
Isradipine
1
1993
3
0.150
Why?
Pyrrolidines
4
1985
15
0.150
Why?
Bradycardia
2
2005
23
0.150
Why?
Solubility
2
2003
37
0.150
Why?
Investigational New Drug Application
1
1992
1
0.140
Why?
Monitoring, Physiologic
4
2008
88
0.140
Why?
International Cooperation
2
2005
35
0.140
Why?
Pain Measurement
1
2015
419
0.140
Why?
Cardiomyopathies
1
2013
31
0.140
Why?
Electric Stimulation Therapy
1
2013
44
0.140
Why?
Competitive Behavior
1
2012
8
0.140
Why?
Economics, Pharmaceutical
2
2003
6
0.140
Why?
Dipyridamole
1
1992
4
0.140
Why?
Unnecessary Procedures
1
2013
30
0.140
Why?
Thallium Radioisotopes
1
1992
6
0.140
Why?
Patient Safety
1
2013
49
0.140
Why?
Double-Blind Method
5
2002
514
0.140
Why?
Chemoprevention
1
2011
7
0.140
Why?
Vitamin K
1
2011
7
0.140
Why?
Factor Xa Inhibitors
1
2011
8
0.130
Why?
Prosthesis Design
1
2014
445
0.130
Why?
Safety-Based Medical Device Withdrawals
1
2011
1
0.130
Why?
Molecular Biology
1
2011
14
0.130
Why?
Comorbidity
2
2011
493
0.130
Why?
Disease Models, Animal
2
2006
761
0.130
Why?
Equipment Failure
1
2011
47
0.130
Why?
Paternalism
1
2010
1
0.130
Why?
Public Policy
2
2001
5
0.130
Why?
Cell- and Tissue-Based Therapy
1
2011
14
0.130
Why?
Florida
1
2010
16
0.120
Why?
Bethanidine
3
1985
3
0.120
Why?
Coronary Artery Disease
2
2004
132
0.120
Why?
Acute Disease
2
2009
260
0.120
Why?
Medicaid
1
2011
38
0.120
Why?
Ticlopidine
1
2010
15
0.120
Why?
Medicare
1
2011
80
0.120
Why?
Industry
1
2010
10
0.120
Why?
Quality of Health Care
1
2012
127
0.120
Why?
Health Care Costs
1
2011
70
0.120
Why?
Publications
1
2010
7
0.120
Why?
Exercise Test
5
1995
106
0.120
Why?
Radioisotopes
1
2009
15
0.120
Why?
Lithium Carbonate
2
2000
4
0.120
Why?
Antimanic Agents
2
2000
12
0.120
Why?
Canada
1
2009
49
0.110
Why?
Linear Models
1
2010
255
0.110
Why?
Hepatorenal Syndrome
1
2009
1
0.110
Why?
Ultrafiltration
1
2009
6
0.110
Why?
Glaucoma
1
2009
5
0.110
Why?
Vasoconstrictor Agents
1
2009
27
0.110
Why?
Glutathione Transferase
1
2009
8
0.110
Why?
Hepatic Encephalopathy
1
2009
6
0.110
Why?
Radiation-Sensitizing Agents
1
2009
13
0.110
Why?
Pacemaker, Artificial
1
2009
23
0.110
Why?
National Institutes of Health (U.S.)
1
2009
28
0.110
Why?
Liver Failure
1
2009
13
0.110
Why?
Renal Insufficiency
1
2009
18
0.110
Why?
Computer Simulation
1
2010
220
0.110
Why?
Protein Isoforms
1
2008
55
0.110
Why?
Bipolar Disorder
2
2000
113
0.110
Why?
Cotinine
1
2008
5
0.110
Why?
Azetidines
1
2008
4
0.110
Why?
Research Subjects
1
2008
11
0.110
Why?
Commerce
1
2008
9
0.110
Why?
Simvastatin
1
2008
15
0.100
Why?
Drug Resistance, Neoplasm
1
2009
71
0.100
Why?
Quality Control
1
2008
47
0.100
Why?
Citrus paradisi
1
2007
1
0.100
Why?
Xenopus
1
2007
5
0.100
Why?
Mental Processes
1
2008
17
0.100
Why?
Prognosis
2
2009
922
0.100
Why?
Maximum Tolerated Dose
1
2007
22
0.100
Why?
Anti-Inflammatory Agents
1
2009
98
0.100
Why?
Legislation, Medical
1
2007
1
0.100
Why?
Motivation
1
2008
92
0.100
Why?
Patient Readmission
1
2009
101
0.100
Why?
Child
2
2003
1337
0.100
Why?
Natriuresis
1
2007
3
0.100
Why?
Injections, Intraperitoneal
1
2007
13
0.100
Why?
Quinolines
1
2007
15
0.100
Why?
Cyclooxygenase 2 Inhibitors
1
2007
30
0.100
Why?
Access to Information
1
2006
5
0.100
Why?
Confidentiality
1
2006
9
0.100
Why?
Substance-Related Disorders
1
2008
105
0.100
Why?
Coated Materials, Biocompatible
1
2007
42
0.090
Why?
Smoking
1
2008
170
0.090
Why?
Prospective Studies
2
2004
1597
0.090
Why?
Blood Vessel Prosthesis Implantation
1
2007
41
0.090
Why?
Predictive Value of Tests
1
2009
584
0.090
Why?
Probability
1
2006
96
0.090
Why?
Ethanol
1
2008
121
0.090
Why?
Databases, Factual
1
2008
314
0.090
Why?
Extracellular Matrix
1
2006
90
0.090
Why?
Enterococcus faecalis
1
2006
8
0.090
Why?
Muscle, Smooth
1
2006
15
0.090
Why?
Benzofurans
1
1986
4
0.090
Why?
Acecainide
1
1985
1
0.090
Why?
Tocainide
4
1986
4
0.090
Why?
Microbial Sensitivity Tests
1
2006
107
0.090
Why?
Antidepressive Agents
2
2004
97
0.090
Why?
Extracellular Fluid
1
2005
4
0.090
Why?
Gene Expression Profiling
1
2006
155
0.090
Why?
Feasibility Studies
1
2006
221
0.090
Why?
Aspirin
1
2006
72
0.090
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2006
98
0.080
Why?
Lethal Dose 50
1
2005
2
0.080
Why?
Incidence
1
2008
724
0.080
Why?
Trans-Activators
1
2005
32
0.080
Why?
Bepridil
4
1985
4
0.080
Why?
Stroke Volume
3
1999
50
0.080
Why?
Lactones
1
2004
14
0.080
Why?
Influenza Vaccines
1
2004
14
0.080
Why?
Sulfones
1
2004
25
0.080
Why?
Guanidines
1
1984
2
0.080
Why?
National Library of Medicine (U.S.)
1
2004
1
0.080
Why?
Recombinant Proteins
1
2005
296
0.080
Why?
Follow-Up Studies
4
2002
1868
0.080
Why?
Colon
1
2006
135
0.080
Why?
Pharmaceutical Solutions
1
2004
3
0.080
Why?
Aconitine
1
2004
1
0.080
Why?
Self Medication
1
2004
3
0.080
Why?
Sleep Initiation and Maintenance Disorders
1
2006
93
0.080
Why?
Cells, Cultured
1
2006
765
0.080
Why?
Purkinje Fibers
1
1983
2
0.080
Why?
Delayed-Action Preparations
1
2003
37
0.080
Why?
Education, Medical, Undergraduate
1
2004
30
0.080
Why?
Oligonucleotide Array Sequence Analysis
1
2004
76
0.080
Why?
Disease Susceptibility
1
2004
73
0.080
Why?
SARS Virus
1
2003
4
0.080
Why?
World Health Organization
1
2003
19
0.070
Why?
Communicable Disease Control
1
2003
10
0.070
Why?
Spinal Cord
3
1980
97
0.070
Why?
Algorithms
1
2006
384
0.070
Why?
Travel
1
2003
15
0.070
Why?
Australia
1
2003
40
0.070
Why?
Encainide
4
1987
7
0.070
Why?
Moricizine
4
1987
6
0.070
Why?
Ventricular Function, Left
1
2002
53
0.070
Why?
Baltimore
1
2002
15
0.070
Why?
Ethics Committees, Research
1
2002
4
0.070
Why?
Biological Warfare
1
2002
3
0.070
Why?
Indicators and Reagents
1
2002
19
0.070
Why?
Civil Defense
1
2002
7
0.070
Why?
Chromatography, High Pressure Liquid
1
2002
43
0.070
Why?
Treatment Failure
1
2002
165
0.070
Why?
Chronic Disease
2
1999
485
0.070
Why?
Cardiac Complexes, Premature
3
1986
3
0.070
Why?
Digitalis Glycosides
2
2001
3
0.070
Why?
Ethics Committees
1
2001
2
0.070
Why?
Professional Staff Committees
1
2001
9
0.070
Why?
Cost-Benefit Analysis
1
2002
127
0.070
Why?
Age Factors
1
2004
833
0.070
Why?
Awareness
1
2001
49
0.070
Why?
Disopyramide
3
1986
3
0.070
Why?
Cognition Disorders
1
2010
1038
0.070
Why?
Hypocalcemia
1
2001
4
0.060
Why?
Informed Consent
1
2001
25
0.060
Why?
Intestinal Absorption
1
2001
40
0.060
Why?
Tilt-Table Test
1
2000
1
0.060
Why?
Histamine Antagonists
1
1980
2
0.060
Why?
Academic Medical Centers
1
2001
136
0.060
Why?
Decision Making, Computer-Assisted
1
2000
6
0.060
Why?
Analysis of Variance
1
2001
362
0.060
Why?
Propranolol
2
1979
13
0.060
Why?
Aging
1
2010
1319
0.060
Why?
Pulmonary Valve Stenosis
1
2019
8
0.060
Why?
Prevalence
1
2002
497
0.060
Why?
Information Storage and Retrieval
1
1999
5
0.060
Why?
Administration, Intravenous
1
2019
32
0.060
Why?
Extracorporeal Membrane Oxygenation
1
2019
10
0.060
Why?
Recurrence
3
1991
344
0.060
Why?
Morbidity
1
1999
64
0.060
Why?
Single-Blind Method
1
1999
122
0.060
Why?
Forecasting
1
1999
127
0.050
Why?
Drug Therapy, Computer-Assisted
1
1998
6
0.050
Why?
Needs Assessment
1
1998
49
0.050
Why?
Resuscitation
1
1997
14
0.050
Why?
Diagnosis, Computer-Assisted
1
1997
18
0.050
Why?
Infant, Newborn
1
2019
665
0.050
Why?
Atrial Flutter
2
1986
13
0.050
Why?
Isosorbide Dinitrate
1
1996
1
0.050
Why?
Echocardiography
1
1997
181
0.040
Why?
Phenytoin
2
1986
12
0.040
Why?
Administration, Sublingual
1
1995
1
0.040
Why?
Ventricular Dysfunction, Left
1
1996
50
0.040
Why?
Data Interpretation, Statistical
1
1995
93
0.040
Why?
Mutation
1
1997
413
0.040
Why?
Infusions, Parenteral
2
1985
14
0.040
Why?
Ajmaline
2
1985
2
0.040
Why?
Aprindine
2
1985
2
0.040
Why?
Bretylium Tosylate
2
1985
2
0.040
Why?
Mexiletine
2
1985
2
0.040
Why?
Propiophenones
2
1985
3
0.040
Why?
Propafenone
2
1985
3
0.040
Why?
Severity of Illness Index
1
1999
1135
0.040
Why?
Cost Sharing
1
1992
2
0.040
Why?
Suspensions
1
1992
4
0.040
Why?
Tablets
1
1992
6
0.040
Why?
Radionuclide Imaging
1
1992
59
0.030
Why?
Metabolic Clearance Rate
1
1991
8
0.030
Why?
Tissue Distribution
1
1991
46
0.030
Why?
Postoperative Complications
1
2019
976
0.030
Why?
Liver
1
1993
201
0.030
Why?
Intestinal Mucosa
1
1993
213
0.030
Why?
Refractory Period, Electrophysiological
2
1987
6
0.030
Why?
Kinetics
3
1985
269
0.030
Why?
Drug Evaluation, Preclinical
1
1987
37
0.030
Why?
Drug Resistance
1
1987
62
0.020
Why?
Fluorobenzenes
1
1986
3
0.020
Why?
Propanolamines
1
1986
11
0.020
Why?
Wolff-Parkinson-White Syndrome
1
1986
2
0.020
Why?
Tachycardia, Paroxysmal
1
1986
3
0.020
Why?
Calcium Channel Blockers
1
1986
37
0.020
Why?
Heart Atria
2
1985
81
0.020
Why?
Metabolic Diseases
1
1985
14
0.020
Why?
Central Nervous System Diseases
1
1985
19
0.020
Why?
Protriptyline
1
1984
1
0.020
Why?
Syncope
1
1984
8
0.020
Why?
Rubidium
1
1983
6
0.020
Why?
Biological Transport, Active
1
1983
19
0.020
Why?
Cats
3
1979
80
0.020
Why?
Promethazine
1
1980
1
0.020
Why?
Cimetidine
1
1980
2
0.020
Why?
Histamine
1
1980
10
0.020
Why?
Histamine H1 Antagonists
1
1980
9
0.020
Why?
Sorbitol
1
1978
4
0.010
Why?
Isosorbide
1
1978
2
0.010
Why?
Microsatellite Repeats
1
1997
18
0.010
Why?
Pedigree
1
1997
71
0.010
Why?
Gene Frequency
1
1997
82
0.010
Why?
Heterozygote
1
1997
97
0.010
Why?
Autonomic Nervous System
1
1976
24
0.010
Why?
Random Allocation
2
1986
157
0.010
Why?
Digitoxin
1
1974
1
0.010
Why?
Catecholamines
1
1993
17
0.010
Why?
Mathematics
1
1985
32
0.010
Why?
Models, Biological
1
1985
413
0.000
Why?
Mouth Floor
1
1978
2
0.000
Why?
Guinea Pigs
1
1976
69
0.000
Why?
Tritium
1
1974
16
0.000
Why?
Somberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description